Editorial Board About Us

Claus G Roehrborn

All articles from this author are listed below.

Volume 6, Number 3 Review Articles

Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction, and Phosphodiesterase-5 Inhibitors

Treatment Update

Claus G Roehrborn

Benign prostatic hyperplasia Erectile dysfunction Phosphodiesterase Lower urinary tractsymptoms

Volume 6, Number 1 Erratum

39-Year-Old Man With Voiding Symptoms

Claus G Roehrborn

Volume 7, Supplement 9 Review Articles

Benign Prostatic Hyperplasia: An Overview

ILC in the Treatment of BPH

Claus G Roehrborn

Benign prostatic hyperplasia Lower urinary tract symptoms Bladder outlet obstruction 5-reductase inhibitors Adrenergic Blockers Interstitial laser coagulation Minimally invasive surgical therapy

Volume 7, Supplement 7 Review Articles

The Development of Lonidamine for Benign Prostatic Hyperplasia and Other Indications

Claus G Roehrborn

Benign prostatic hyperplasia High-grade prostatic intraepithelial neoplasia Lonidamine Metabolic targeting Krebs cycle Cancer treatment

Volume 7, Supplement 8 Review Articles

Combination Medical Therapy for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

Claus G Roehrborn

Benign prostatic hyperplasia Lower urinary tract symptoms Adrenergic Blockers

Volume 7, Supplement 4 Review Articles

Acute Urinary Retention: Risks and Management

Claus G Roehrborn

Benign prostatic hyperplasia Transurethral resection Acute urinary retention

Volume 7, Supplement 4 Review Articles

Historical Overview of Medical Therapy for Benign Prostatic Hyperplasia

Claus G Roehrborn Herbert Lepor

Volume 8, Number 4 Meeting Reviews

Advances in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

Meeting Review

Claus G Roehrborn

Highlights from the 21st European Association of Urology Congress, April 5–8, 2006, Paris, France [Rev Urol. 2006;8(4):216-225]

Benign prostatic hyperplasia Nocturia Lower urinary tract symptoms Alfuzosin Prostatectomy PDE-5 inhibitors TURP Dutasteride Sexual dysfunction Acute urinary retention Chronic inflammatory infiltrates PVP High-energy transurethral microwave thermotherapy

Volume 8, Supplement 3 Review Articles

Safety and Efficacy of the Potassium-Titanyl-Phosphate Laser and Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia

Photoselective Vaporization of the Prostate

Claus G Roehrborn

The currently commercially available 80-W potassium-titanyl-phosphate laser used for photoselective vaporization of the prostate in men with lower urinary tract symptoms and benign prostatic hyperplasia (BPH) is a safe and effective therapeutic alternative for a wide spectrum of prostate sizes and configurations. Efficacy data from multicenter prospective studies, comparative studies against other interventions, and single-center long-term outcomes suggest the efficacy to be at least equivalent to that of transurethral resection of the prostate, with a very good safety profile. New technological developments promise to further enhance the utility of this laser for application in BPH and urology. [Rev Urol. 2006;8(suppl 3):S16-S23]

Benign prostatic hyperplasia Lower urinary tract symptoms Potassium-titanyl-phosphate laser Laser prostatec-tomy Photoselective vaporization of the prostate